These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 32694521)
1. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Yu JJ; Zhou DD; Yang XX; Cui B; Tan FW; Wang J; Li K; Shang S; Zhang C; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Huang B; Hua F; Hu ZW Nat Commun; 2020 Jul; 11(1):3660. PubMed ID: 32694521 [TBL] [Abstract][Full Text] [Related]
2. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
3. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Bertran-Alamillo J; Cattan V; Schoumacher M; Codony-Servat J; Giménez-Capitán A; Cantero F; Burbridge M; Rodríguez S; Teixidó C; Roman R; Castellví J; García-Román S; Codony-Servat C; Viteri S; Cardona AF; Karachaliou N; Rosell R; Molina-Vila MA Nat Commun; 2019 Apr; 10(1):1812. PubMed ID: 31000705 [TBL] [Abstract][Full Text] [Related]
4. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling. Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029 [TBL] [Abstract][Full Text] [Related]
9. Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer. Tran TTT; Phung CD; Yeo BZJ; Prajogo RC; Jayasinghe MK; Yuan J; Tan DSW; Yeo EYM; Goh BC; Tam WL; Le MTN EBioMedicine; 2024 Oct; 108():105356. PubMed ID: 39303667 [TBL] [Abstract][Full Text] [Related]
10. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
11. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Niu M; Xu J; Liu Y; Li Y; He T; Ding L; He Y; Yi Y; Li F; Guo R; Gao Y; Li R; Li L; Fu M; Hu Q; Luo Y; Zhang C; Qin K; Yi J; Yu S; Yang J; Chen H; Wang L; Li Z; Dong B; Qi S; Ouyang L; Zhang Y; Cao Y; Xiao ZJ Nat Commun; 2021 Oct; 12(1):5919. PubMed ID: 34635651 [TBL] [Abstract][Full Text] [Related]
12. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer. Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533 [TBL] [Abstract][Full Text] [Related]
13. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010 [TBL] [Abstract][Full Text] [Related]
14. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Li K; Wang F; Yang ZN; Zhang TT; Yuan YF; Zhao CX; Yeerjiang Z; Cui B; Hua F; Lv XX; Zhang XW; Yu JJ; Liu SS; Yu JM; Shang S; Xiao Y; Hu ZW Nat Commun; 2020 Dec; 11(1):6316. PubMed ID: 33298911 [TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
16. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710 [TBL] [Abstract][Full Text] [Related]
17. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632 [No Abstract] [Full Text] [Related]
18. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations. Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937 [TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255 [No Abstract] [Full Text] [Related] [Next] [New Search]